van der Velden, D. L.
Hoes, L. R.
van der Wijngaart, H.
van Berge Henegouwen, J. M.
van Werkhoven, E.
Roepman, P.
Schilsky, R. L.
de Leng, W. W. J.
Huitema, A. D. R.
Nuijen, B.
Nederlof, P. M.
van Herpen, C. M. L.
de Groot, D. J. A.
Devriese, L. A.
Hoeben, A.
de Jonge, M. J. A.
Chalabi, M.
Smit, E. F.
de Langen, A. J.
Mehra, N.
Labots, M.
Kapiteijn, E.
Sleijfer, S.
Cuppen, E.
Verheul, H. M. W.
Gelderblom, H.
Voest, E. E.
Article History
Received: 21 July 2018
Accepted: 14 August 2019
First Online: 30 September 2019
Competing interests
: E.E.V. is legally responsible for all contracts with pharmaceutical companies at the Netherlands Cancer Institute. H.M.W.V. and H.G. have, through the DRUP and other studies, received support from pharmaceutical companies that are participating in the DRUP. R.L.S serves as principal investigator for the TAPUR trial, in support of which the American Society of Clinical Oncology receives financial support from Astra-Zeneca, Bayer, Bristol-Myers Squibb, Genentech, Lilly, Merck and Pfizer. C.M.L.v.H. has received funding from AstraZeneca, BMS, Ipsen, Merck, MSD and Novartis. A.J.d.L. has served as an advisor for AstraZeneca, BMS, Boehringer, Pfizer, Lilly and MSD, and has received research grants from AstraZeneca, BMS and MSD. E.K. has served as advisor for Amgen, BMS, Eisai, Genzyme-Sanofi, MSD, Novartis and Roche. The other authors declare no competing interests.